These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18086752)

  • 1. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
    Kothmaier H; Quehenberger F; Halbwedl I; Morbini P; Demirag F; Zeren H; Comin CE; Murer B; Cagle PT; Attanoos R; Gibbs AR; Galateau-Salle F; Popper HH
    Thorax; 2008 Apr; 63(4):345-51. PubMed ID: 18086752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
    Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
    Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
    Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
    Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
    Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
    Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
    Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
    Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
    Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
    Lindholm PM; Soini Y; Myllärniemi M; Knuutila S; Heikinheimo M; Kinnula VL; Salmenkivi K
    J Clin Pathol; 2009 Apr; 62(4):339-44. PubMed ID: 19060016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
    Rena O; Boldorini LR; Gaudino E; Casadio C
    J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
    Frey AB; Wali A; Pass H; Lonardo F
    Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
    Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
    Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts in malignant pleural mesothelioma.
    Kaufman AJ; Pass HI
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):293-303. PubMed ID: 18279069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
    Catalano A; Lazzarini R; Di Nuzzo S; Orciari S; Procopio A
    Cancer Res; 2009 Feb; 69(4):1485-93. PubMed ID: 19176370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
    Kobayashi M; Takeuchi T; Ohtsuki Y
    Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions.
    Ascoli V; Scalzo CC; Facciolo F; Nardi F
    Acta Cytol; 1995; 39(4):613-22. PubMed ID: 7543232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
    Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
    Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
    Destro A; Ceresoli GL; Falleni M; Zucali PA; Morenghi E; Bianchi P; Pellegrini C; Cordani N; Vaira V; Alloisio M; Rizzi A; Bosari S; Roncalli M
    Lung Cancer; 2006 Feb; 51(2):207-15. PubMed ID: 16384623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
    O'Byrne KJ; Edwards JG; Waller DA
    Lung Cancer; 2004 Aug; 45 Suppl 1():S45-8. PubMed ID: 15261433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.